Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study.
Autor: | Heysell, Scott K, Mpagama, Stellah G, Ogarkov, Oleg B, Conaway, Mark, Ahmed, Shahriar, Zhdanova, Svetlana, Pholwat, Suporn, Alshaer, Mohammad H, Chongolo, Anna M, Mujaga, Buliga, Sariko, Margaretha, Saba, Sabrina, Rahman, S M Mazidur, Uddin, Mohammad Khaja Mafij, Suzdalnitsky, Alexey, Moiseeva, Elena, Zorkaltseva, Elena, Koshcheyev, Mikhail, Vitko, Serhiy, Mmbaga, Blandina T |
---|---|
Předmět: |
CONFIDENCE intervals
HETEROCYCLIC compounds PYRAZINAMIDE TREATMENT effectiveness TREATMENT failure ANTITUBERCULAR agents DESCRIPTIVE statistics DOSE-effect relationship in pharmacology RESEARCH funding RIFAMPIN ODDS ratio RECEIVER operating characteristic curves QUINOLONE antibacterial agents PHARMACODYNAMICS |
Zdroj: | Clinical Infectious Diseases; 2/1/2023, Vol. 76 Issue 3, p497-505, 9p |
Abstrakt: | Background Rifampin-resistant and/or multidrug-resistant tuberculosis (RR/MDR-TB) treatment requires multiple drugs, and outcomes remain suboptimal. Some drugs are associated with improved outcome. It is unknown whether particular pharmacokinetic-pharmacodynamic relationships predict outcome. Methods Adults with pulmonary RR/MDR-TB in Tanzania, Bangladesh, and the Russian Federation receiving local regimens were enrolled from June 2016 to July 2018. Serum was collected after 2, 4, and 8 weeks for each drug's area under the concentration-time curve over 24 hours (AUC |
Databáze: | Complementary Index |
Externí odkaz: |